CORT

Current Thesis

Post-CRL redemption arc: first-in-class SGRA (Lifyorli/relacorilant) got FDA approval 2026-03-25 in platinum-resistant ovarian cancer after the hypercortisolism CRL crushed the stock -50% on 2025-12-31 ($70 → $34.80). The narrative is now pivoting from "broken NDA / value trap" to "first-in-class oncology launch + platform rebuild," reinforced by 2026-04-10 ROSELLA final OS (35% mortality reduction) and an NCCN preferred-regimen upgrade. We'd be buying the recovery leg on a durable platform-story reframe, but the Q1 print (est. early May) is the first binary that either validates or kills it. This is a messy post-crash chart, not a clean trend — sizing discipline matters.

Bull Case

• 2026-03-25 FDA approval of Lifyorli™ (relacorilant) + nab-paclitaxel in platinum-resistant ovarian cancer — first-in-class selective glucocorticoid receptor antagonist; stock +13% on print. Specialty oncology list price $37,900 / 28-day cycle — unusually high for a former endocrine-only shop.
• 2026-04-10 ROSELLA final overall survival showed 35% reduction in risk of death vs nab-paclitaxel alone (n=381); simultaneous Lancet publication + NCCN Guidelines preferred regimen upgrade = sell-side model unlock + hospital formulary tailwind.
• Revenue trajectory still accelerating on Korlym alone — Q3 2025 revenue $207.6M (vs $182.5M YoY, +13.7%); FY2025 guided $800–850M; FY2026 guided $900M–$1.0B. Growth is organic from Cushing's Rx share, not acquisition-fueled.
• Cushing's resubmission optionality — the 2025-12-31 CRL rejected the hypercortisolism NDA for "additional evidence of effectiveness," not safety or trial failure. GRACE met its primary endpoint; GRADIENT was confirmatory. A resubmission using ovarian-cancer safety data could re-open the much bigger Cushing's opportunity in H2 2026 / 2027.
• Analyst distribution is fat-tailed to the upside: 6-analyst avg 12-mo PT $130 (Public.com), some bull models $1.8B revenue / $558M EPS by 2028. UBS peak-sales estimate $550M just for Lifyorli even without Cushing's.
• Platform, not single-asset — pipeline runs SGRA candidates into solid tumors, ALS, liver disease; Lifyorli approval de-risks the mechanism and validates the whole chess board.

Bear Case

• The 2025-12-31 CRL reset is unresolved — stock still well below pre-CRL $70 level; no PDUFA for Cushing's resubmission has been disclosed. If resubmission slips to 2027 or requires a new trial, FY26/27 earnings power is capped.
• Active securities class action (Hagens Berman, lead plaintiff deadline 2026-04-21) alleging misleading statements re: relacorilant. Adds headline risk into any earnings print and creates a sell-the-news risk on every bounce.
• Peak-sales estimates diverge 10x ($150M Clarivate ↔ $1.8B bull models). That's not analyst noise — that's structural uncertainty about ovarian-cancer penetration given a steroid contraindication (flagged by UBS).
• Platinum-resistant ovarian is a small, contested market — bevacizumab pre-treatment is a narrow funnel, and $37,900/cycle pricing invites payor pushback.
• Korlym patent cliff and generic mifepristone threat still overhangs the legacy revenue base that funds the pipeline.
• Chart structure is broken — came off $117 high in 2025, crashed to $28.66, has not reclaimed the 200-EMA. Every bounce is a lower-high until proven otherwise.

Setup & Price Structure

• Archetype: 5 — Binary Catalyst (post-CRL recovery + first-in-class launch + pending Cushing's resubmission).
• 52-week range: $28.66 – $117.33. Deep crash crater; trading in lower third of range.
• Key levels:
• Support: 2025-12-31 CRL low ~$28.66 (do-not-break line)
• Recent base: ~$34–$38 (post-CRL consolidation through March 2026)
• Breakout trigger: reclaim of 200-EMA (approx. $55–60 zone) on volume — that's the "narrative-repaired" signal
• Resistance: $70 pre-CRL level → if reclaimed, opens full retrace to $117 high
• Tape: Two clean gap-ups on real catalysts (2026-03-25 +13% on approval, 2026-04-10 +5.9% on OS data + NCCN). Higher-low structure forming off $28 — tentative ACCELERATING.
• Theme status: biotech-precision-therapeutics — ACCELERATING at the Lifyorli launch level, but the stock is still in recovery mode from a broken chart. Not stretched above MA; no peak retail sentiment yet (class action is keeping bag-holders scared).
• Beginner-trap check: not overextended, not euphoric, not pre-earnings gamble yet — but Q1 print is close, so timing-window is narrow.

Catalyst Calendar (next 30 days)

• ~2026-04-21 — Securities class action lead plaintiff deadline (Hagens Berman). Headline risk; not tradeable but watch for follow-on coverage.
• ~2026-05-05 (est.) — Q1 2026 earnings — binary. Watch for: (1) Lifyorli launch trajectory commentary / early scripts, (2) reaffirmation of $900M–$1.0B 2026 guide, (3) updated Cushing's resubmission timeline. Miss on either kills the thesis.
• Rolling — NCCN formulary adoption updates; specialty pharmacy Lifyorli script-data leaks.
• Window: 2026-07-11 PDUFA already cleared by early approval — the next hard FDA date is whenever Corcept resubmits the Cushing's NDA. Not in the 30-day window, but is the biggest medium-term re-rating lever.

What Would Change Our Mind

• Weekly close below $32 (below the post-CRL base) → chart broken, recovery failed, exit. Stop level.
• Q1 2026 revenue <$195M (below Q3 2025 $207.6M run rate) OR FY26 guide cut below $900M low end → growth story breaks, thesis invalidated.
• Cushing's resubmission timeline slips to 2027 or requires new Phase 3 → platform story caps at ovarian-cancer single-asset; de-rate to $35 range.
• Class action develops into restated financials or management departure → headline death spiral, skip.
• Lifyorli early script data shows <200 patients in first 90 days → launch is weaker than the $550M UBS peak implies; trim.
• Conversely: reclaim of 200-EMA (~$55–60) on volume + Cushing's resubmission date announced → conviction upgrade to HIGH, add on pullbacks to 20-EMA.

Correlation Notes

• SPDR XBI / biotech beta — CORT correlates with small/mid-cap biotech risk-on regime. If XBI rolls over, recovery-arc names like CORT get sold indiscriminately regardless of news.
• Rate-cycle sensitivity — non-profitable / speculative pipeline biotech trades inverse to 10Y yields. Currently profitable (Korlym cash flow) so less rate-sensitive than pure clinical-stage peers, but still a factor.
• Ovarian cancer peers — watch IMGN (Elahere), GSK (Zejula), CLVS-legacy assets for competitive flow data. Lifyorli doesn't compete with PARPs directly but payors read the whole basket.
• Generic mifepristone overhang — any Teva / Lupin announcement on generic Korlym is a -10% overnight event.
• Theme cluster: biotech-precision-therapeutics sibling names with first-in-class approvals in 2025-26 (e.g. VKTX obesity, MDGL MASH, VRTX non-opioid) can provide confirmation/denial of the "first-in-class launch goes parabolic" template.